β-thalassaemia
Showing 1 - 25 of 1,062
Transfusion Dependent Beta-Thalassaemia Trial in Nanning (ET-01)
Recruiting
- Transfusion Dependent Beta-Thalassaemia
- ET-01
-
Nanning, Guangxi, ChinaPLA 923 Hospital
Mar 2, 2023
Transfusion Dependent Beta-Thalassaemia Trial in Guangzhou, Shenzhen, Tianjin (ET-01)
Active, not recruiting
- Transfusion Dependent Beta-Thalassaemia
- ET-01
-
Guangzhou, Guangdong, China
- +3 more
May 9, 2022
Transfusion Dependent Beta-Thalassaemia Trial in Tianjin (ET-01)
Active, not recruiting
- Transfusion Dependent Beta-Thalassaemia
- ET-01
-
Tianjin, Tianjin, ChinaInstitute of Hematology & Blood Diseases Hospital
Dec 9, 2021
Sickle Cell Disease, Sickle Cell Trait, Beta-Thalassemia Trial (High performance liquid chromatography, Automated sickling test,
Not yet recruiting
- Sickle Cell Disease
- +4 more
- High performance liquid chromatography
- +5 more
- (no location specified)
Aug 17, 2022
Thalassemia Major, Transfusion-dependent Anemia Trial in Guangzhou (Luspatercept Injectable Product)
Recruiting
- Thalassemia Major
- Transfusion-dependent Anemia
- Luspatercept Injectable Product
-
Guangzhou, Guangdong, ChinaThe second affiliated hospital of Sun Yat-sen University
Jul 15, 2022
ß-thalassemia Trial in Shenzhen (ß-globin restored autologous hematopoietic stem cells)
Recruiting
- β-thalassemia
- β-globin restored autologous hematopoietic stem cells
-
Shenzhen, Guangdong, ChinaShenzhen Children's Hospital
Feb 24, 2023
Transfusion-dependent ß-thalassemia Patients, Cardiac Iron Overload Trial in Athens, Patras (Deferasirox, Deferoxamine (DFO))
Terminated
- Transfusion-dependent β-thalassemia Patients
- Cardiac Iron Overload
- Deferasirox
- Deferoxamine (DFO)
-
Athens, GR, Greece
- +3 more
Oct 21, 2019
ß-thalassemia Trial in Shenzhen (ß-globin restored autologous hematopoietic stem cells)
Recruiting
- β-thalassemia
- β-globin restored autologous hematopoietic stem cells
-
Shenzhen, Guangdong, ChinaShenzhen University General Hospital
May 8, 2023
The Prevelence of HBB c.93-21 G-A in ß Thalassemia Patients
Recruiting
- Beta-Thalassemia
- ARMS PCR
-
Assiut, EgyptFaculty of Medicine Assiut University
Jan 30, 2023
Transfusion-dependent Beta-Thalassemia Trial in Tianjin (KL003 cell injection Drug Product)
Not yet recruiting
- Transfusion-dependent Beta-Thalassemia
- KL003 cell injection Drug Product
-
Tianjin, Tianjin, ChinaRegenerative Medicine Center
May 8, 2023
The Prevelence of IVS 1-6 [HBB:c.92 +6 T-C] Gene Mutation in
Not yet recruiting
- Beta-Thalassemia
- ARMS
- (no location specified)
May 10, 2022
Transfusion-dependent Beta-Thalassemia Trial in Peshawar (Thalidomide)
Completed
- Transfusion-dependent Beta-Thalassemia
-
Peshawar, Khyber Pakhtunkhwa, PakistanBlood Care Clinic
Nov 19, 2023
Beta Thalassemia Intermedia Trial in Worldwide (IONIS TMPRSS6-LRx)
Active, not recruiting
- Beta Thalassemia Intermedia
-
Camperdown, New South Wales, Australia
- +18 more
Sep 23, 2022
Beta Thalassemia Major, Beta Thalassemia Intermedia Trial in Worldwide (SOTATERCEPT (ACE-011))
Completed
- Beta Thalassemia Major
- Beta Thalassemia Intermedia
- SOTATERCEPT (ACE-011)
-
Créteil, France
- +14 more
Aug 18, 2022
Transfusion Dependent Beta-Thalassemia Trial in Nanning (GMCN-508B (LentiRed))
Recruiting
- Transfusion Dependent Beta-Thalassemia
- GMCN-508B (LentiRed)
-
Nanning, Guangxi, ChinaThe affiliated hospital of guangxi medical university
Feb 28, 2023
Genetic and Haematological Modifiers of SCD Severity in Kaduna
Not yet recruiting
- Sickle Cell Disease
- (no location specified)
Apr 27, 2023
Beta-Thalassemia Trial in Bulgaria, Israel, United States (VIT-2763 60 mg QD, VIT-2763 60 mg BID, VIT-2763 120 mg BID)
Withdrawn
- Beta-Thalassemia
- VIT-2763 60 mg QD
- +3 more
-
Whittier, California
- +6 more
Nov 7, 2022
Beta-Thalassemia Trial in Ferrara, Firenze, Pisa (Sirolimus 0.5 mg)
Recruiting
- Beta-Thalassemia
- Sirolimus 0.5 mg
-
Ferrara, FE, Italy
- +3 more
Nov 11, 2021
Thalassemia, Iron Overload Trial in Nanning (CN128 Tablets)
Recruiting
- Thalassemia
- Iron Overload
- CN128 Tablets
-
Nanning, Guangxi, ChinaThe First Affiliated Hospital Of Guangxi Medical University
Aug 3, 2022
Non-transfusion-dependent Thalassemia, Low Risk Myelodysplastic Syndrome, Very-Low Risk Myelodysplastic Syndrome Trial in
Recruiting
- Non-transfusion-dependent Thalassemia
- +2 more
- SLN124
- Placebo
-
Düsseldorf, Germany
- +19 more
Mar 18, 2022
Thalassemia, Beta, Thalassemia Major Trial in Tianjin (VGB-Ex01)
Not yet recruiting
- Thalassemia, Beta
- Thalassemia Major
- VGB-Ex01
-
Tianjin, Tianjin, ChinaRegenerative Medicine Center
Sep 11, 2023
Pumilio1 Expression, Sickle Cell Anemia, ß-thalassemia
Not yet recruiting
- Sickle Cell Disease, Beta Thalassemia Intermedia
- RNA Binding Protein Pumilio1 (PUM1) Expression by reverse transcriptase quantatative PCR
- (no location specified)
May 30, 2023
Bioavailability Trial in Stuttgart (Control beta-carotene supplement plus Placebo, Control beta-carotene supplement plus iron
Completed
- Bioavailability
- iron and zinc suphate supplements
-
Stuttgart, Baden-Württemberg, GermanyUniversity of Hohenheim
Apr 28, 2023
ß-thalassemia Trial in Shanghai (BD211)
Not yet recruiting
- β-thalassemia
- BD211
-
Shanghai, ChinaShanghai Ruijin Hospital
Mar 16, 2023
ß-thalassemia Trial (BD211)
Not yet recruiting
- β-thalassemia
- BD211
- (no location specified)
Mar 15, 2023